Skip to main content
. 2022 Dec 31;67:62–70. doi: 10.1016/j.breast.2022.12.033

Table 4.

Table summarizing studies analyzing contraception in BC survivors.

Author and study Year of inclusion Country Design Total number patients Patients Age inclusion criteria Median age Number BC patients Controls Source of controls Rate of contraceptive counseling Contraceptive prevalence in women at risk of becoming pregnant unintentionally Factors associated with contraceptive prevalence
Quinn et al., [13]
Contraception
2010 USA Written or online survey 476 Non gynecological cancer <40 years old at diagnosis 31,1 86 51 277 General population estimation via the 2006–2010 National Survey for Family Growth 66.7% Unintended pregnancy risk:
21%
Lower use of tiers I-II:
Increasing age: 1.07 per year; 95% CI [1.02–1.12]; p = 0.006
Previous BC history:
OR 2.14; 95% CI [1.10–4.17]; p = 0.025
Maslow et al., [12]
Contraception
2011–2012 USA Online survey 107 Within 5 years of a cancer diagnosis 18–45 years old at study inclusion 56 65% 57% Higher use of tiers I-II:
Contraceptive counseling: OR 6.92; 95% CI [1.14–42.11]; p = 0.036
Non BC diagnosis: OR 3.60; 95% CI [1.03–12.64]; p = 0.046
Dominick et al., [10]
Obstetrics & Gynecology
2011–2013 USA Annual online or telephone survey 295 Cancer survivors 18–44 years old at study inclusion 31,6 91 56% 84% Higher use of tiers I-II:
Family planning consult <1 year: RR 1.; 95% CI [1.1–1.5]; p < 0.01
Lower use of tiers I-II:
≥31 years old: RR 0.62; 95% CI [0.5–0.8]; p < 0.01
<2 years since cancer diagnosis:RR 0.66; 95% CI [0.5–0.9]; p < 0.01
BC diagnosis: RR 0.45; 95% CI [0.3–0.7]; p < 0.01
Hadnott et al., [24]
Fertility and Sterility
2015–2017 USA Online survey 483 Cancer survivors 18–40 years old at study inclusion 34 113 31% 84% Lower use of contraception:
Chemotherapy: PR 1.7; 95% CI [1.1–2.7]
History of infertility: PR 2.; 95% CI [1.9–4.3]
Infertility perception: PR 4.0, 95% CI [2.5–7.4]
Mody et al., [21]
J Cancer Surviv
2014–2015 USA Online survey 150 History of Breast cancer within 5 years 18–50 years old at study inclusion 37,3 150 61% 83% NA
Lambertini et al, [18]
JAMA Network Open
2012–2017 France Longitudinal evaluation 2900 Breast cancer survivors 18–50 years old at study inclusion 43,1 2900 45% at year 1 and 65.7% at year 2 during breast
cancer follow-up
38.9% at year 1 and 41.2% at year 2 during breast cancer follow-up Higher use of contraception
Using contraception at diagnosis: aOR: 4.02; 95% CI [3.15–5.14],
Being younger: aOR, 1.09; 95% CI, 1.07–1.13 per each decreasing year), having better sexual function aOR: 1.13; 95% CI [1.07–1.19], Having children: aOR: 4.21; 95% CI [1.8–9.86], Presence of leukorrhea: aOR: 1.32, 95% CI [1.03–1.7], Tamoxifen treatment
alone: aOR: 1.39; 95% CI [1.01–1.92], Gynecologist follow-up at 1 year: aOR
: 1.29; 95% CI [1.02–1.63], Partnered status: aOR: 1.61; 95% CI [1.07–2.44]
Our study (2022) 2018–2019 France Online survey 517 Breast cancer survivors 18–43 years old at study inclusion 37,1 517 1034 Controls from the research network matched on age and parity 66,30% 78.9% Higher use of contraception:
Younger age: OR 0.91; 95% CI [0.85–0.98]; p = 0.011
Information at BC diagnosis about chemo-induced ovarian damage: OR 2.47; 95% CI [1.39–4.37]; p = 0.002
Contraception information at BC diagnosis: OR 1.86; 95% CI [1.07–3.2]; p = 0.026
Anti-HER2 treatment: OR 2.46; 95% CI [1.39–6.16]; p = 0.018